Page 94 - 2022_02-Haematologica-web

H. Schmid et al.
CD1d molecules. Immunogenetics. 1999;
50(3-4):146-151.
27. Haraguchi K, Takahashi T, Hiruma K, et al.
Recovery of Valpha24+ NKT cells after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2004;34(7):595- 602.
28. Chen YB, Efebera YA, Johnston L, et al. Increased Foxp3(+)Helios(+) regulatory T cells and decreased acute graft-versus-host disease after allogeneic bone marrow trans- plantation in patients receiving Sirolimus and RGI-2001, an activator of invariant nat- ural killer T cells. Biol Blood Marrow Transplant. 2017;23(4):625-634.
29. Reddy P. Pathophysiology of acute graft- versus-host disease. Hematol Oncol. 2003; 21(4):149-161.
30. Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004;172(12):7393-7398.
31. Zhang Y, Louboutin JP, Zhu J, Rivera AJ, Emerson SG. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell- mediated acute graft-versus-host disease. J Clin Invest. 2002;109(10):1335-1344.
32.Coman T, Rossignol J, D'Aveni M, et al. Human CD4- invariant NKT lymphocytes regulate graft versus host disease. Oncoimmunology. 2018;7(11):e1470735.
33. Liu TY, Uemura Y, Suzuki M, et al. Distinct subsets of human invariant NKT cells dif- ferentially regulate T helper responses via dendritic cells. Eur J Immunol. 2008; 38(4):1012-1023.
34. Exley M, Garcia J, Balk SP, Porcelli S. Requirements for CD1d recognition by human invariant Valpha24+ CD4-CD8- T cells. J Exp Med. 1997;186(1):109-120.
35. Wingender G, Krebs P, Beutler B, Kronenberg M. Antigen-specific cytotoxici- ty by invariant NKT cells in vivo is
CD95/CD178-dependent and is correlated with antigenic potency. J Immunol. 2010; 185(5):2721-2729.
36. Mattarollo SR, Kenna T, Nieda M, Nicol AJ. Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity. Int J Cancer. 2006;119(7):1630-1637.
37. Nieda M, Nicol A, Koezuka Y, et al. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood. 2001;97(7):2067-2074.
38. Kawano T, Cui J, Koezuka Y, et al. Natural killer-like nonspecific tumor cell lysis medi- ated by specific ligand-activated Valpha14 NKT cells. Proc Natl Acad Sci U S A. 1998;95(10):5690-5693.
39. Nicol A, Nieda M, Koezuka Y, et al. Human invariant valpha24+ natural killer T cells activated by alpha-galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology. 2000;99(2):229-234.
40. Beilke JN, Kuhl NR, Van Kaer L, Gill RG. NK cells promote islet allograft tolerance via a perforin-dependent mechanism. Nat Med. 2005;11(10):1059-1065.
41. Watowich SS, Liu YJ. Mechanisms regulat- ing dendritic cell specification and develop- ment. Immunol Rev. 2010;238(1):76-92.
42. Manz MG, Traver D, Miyamoto T, Weissman IL, Akashi K. Dendritic cell potentials of early lymphoid and myeloid progenitors. Blood. 2001;97(11):3333-3341.
43. Yu H, Tian Y, Wang Y, Mineishi S, Zhang Y. Dendritic cell regulation of graft-vs.-host disease: immunostimulation and tolerance. Front Immunol. 2019;10:93.
44.Collin M, Bigley V. Human dendritic cell subsets: an update. Immunology. 2018;154(1):3-20.
45. Koyama M, Hashimoto D, Aoyama K, et al. Plasmacytoid dendritic cells prime alloreactive T cells to mediate graft-versus- host disease as antigen-presenting cells. Blood. 2009;113(9):2088-2095.
46.Markey KA, Banovic T, Kuns RD, et al. Conventional dendritic cells are the critical donor APC presenting alloantigen after experimental bone marrow transplanta- tion. Blood. 2009;113(22):5644-5649.
47. Martinez-Cingolani C, Grandclaudon M, Jeanmougin M, Jouve M, Zollinger R, Soumelis V. Human blood BDCA-1 den- dritic cells differentiate into Langerhans- like cells with thymic stromal lymphopoi- etin and TGF-beta. Blood. 2014; 124(15): 2411-2420.
48.Ito T, Inaba M, Inaba K, et al. A CD1a(+)/CD11c(+) subset of human blood dendritic cells is a direct precursor of Langerhans cells. J Immunol. 1999;163(3): 1409-1419.
49. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interfer- on-producing cells in human blood. Science. 1999;284(5421):1835-1837.
50. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5(8):919-923.
51.Lu Y, Giver CR, Sharma A, et al. IFN- gamma and indoleamine 2,3-dioxygenase signaling between donor dendritic cells and T cells regulates graft versus host and graft versus leukemia activity. Blood. 2012; 119(4):1075-1085.
52. Hassan M, Ulezko Antonova A, Li JM, et al. Flt3L Treatment of bone marrow donors increases graft plasmacytoid dendritic cell content and improves allogeneic transplan- tation outcomes. Biol Blood Marrow Transplant. 2019;25(6):1075-1084.
436
haematologica | 2022; 107(2)